KR20040095240A - 치환된 3-페닐-5-알콕시-1,3,4-옥사디아졸-2-온, 이의제조방법 및 약물에서의 이의 용도 - Google Patents

치환된 3-페닐-5-알콕시-1,3,4-옥사디아졸-2-온, 이의제조방법 및 약물에서의 이의 용도 Download PDF

Info

Publication number
KR20040095240A
KR20040095240A KR10-2004-7013485A KR20047013485A KR20040095240A KR 20040095240 A KR20040095240 A KR 20040095240A KR 20047013485 A KR20047013485 A KR 20047013485A KR 20040095240 A KR20040095240 A KR 20040095240A
Authority
KR
South Korea
Prior art keywords
formula
compound
alkyl
phenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2004-7013485A
Other languages
English (en)
Korean (ko)
Inventor
쇠나핑거카를
페트리슈테판
뮐러귄터
바우어아르민
호이어후베르트옷토
Original Assignee
아벤티스 파마 도이칠란트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마 도이칠란트 게엠베하 filed Critical 아벤티스 파마 도이칠란트 게엠베하
Publication of KR20040095240A publication Critical patent/KR20040095240A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
KR10-2004-7013485A 2002-02-28 2003-02-14 치환된 3-페닐-5-알콕시-1,3,4-옥사디아졸-2-온, 이의제조방법 및 약물에서의 이의 용도 Withdrawn KR20040095240A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10208987A DE10208987A1 (de) 2002-02-28 2002-02-28 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE10208987.6 2002-02-28
PCT/EP2003/001484 WO2003072555A1 (de) 2002-02-28 2003-02-14 Substituierte 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-one sowie ihre herstellung und verwendung in arzneistoffen

Publications (1)

Publication Number Publication Date
KR20040095240A true KR20040095240A (ko) 2004-11-12

Family

ID=27740558

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7013485A Withdrawn KR20040095240A (ko) 2002-02-28 2003-02-14 치환된 3-페닐-5-알콕시-1,3,4-옥사디아졸-2-온, 이의제조방법 및 약물에서의 이의 용도

Country Status (22)

Country Link
EP (1) EP1480960B1 (enExample)
JP (1) JP4486363B2 (enExample)
KR (1) KR20040095240A (enExample)
CN (1) CN1639137A (enExample)
AR (1) AR038701A1 (enExample)
AT (1) ATE557012T1 (enExample)
AU (1) AU2003226977A1 (enExample)
BR (1) BR0307921A (enExample)
CA (1) CA2477031A1 (enExample)
CO (1) CO5611146A2 (enExample)
DE (1) DE10208987A1 (enExample)
HR (1) HRP20040782A2 (enExample)
HU (1) HUP0402671A3 (enExample)
IL (1) IL163683A0 (enExample)
MA (1) MA27172A1 (enExample)
MX (1) MXPA04007960A (enExample)
NO (1) NO20044090L (enExample)
PE (1) PE20030928A1 (enExample)
PL (1) PL370423A1 (enExample)
RU (1) RU2004128933A (enExample)
TW (1) TW200400951A (enExample)
WO (1) WO2003072555A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
CA2710743A1 (en) * 2007-12-27 2009-07-09 Bial-Portela & Ca., S.A. 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
TW201028406A (en) 2008-12-23 2010-08-01 Bial Portela & Ca Sa 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
WO2001066531A1 (de) * 2000-03-07 2001-09-13 Aventis Pharma Deutschland Gmbh Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Also Published As

Publication number Publication date
HRP20040782A2 (en) 2005-02-28
NO20044090L (no) 2004-11-04
PE20030928A1 (es) 2003-12-17
EP1480960B1 (de) 2012-05-09
EP1480960A1 (de) 2004-12-01
AU2003226977A1 (en) 2003-09-09
AR038701A1 (es) 2005-01-26
JP4486363B2 (ja) 2010-06-23
CO5611146A2 (es) 2006-02-28
MA27172A1 (fr) 2005-01-03
CN1639137A (zh) 2005-07-13
RU2004128933A (ru) 2005-04-20
BR0307921A (pt) 2004-12-21
MXPA04007960A (es) 2004-11-26
ATE557012T1 (de) 2012-05-15
TW200400951A (en) 2004-01-16
IL163683A0 (en) 2005-12-18
HUP0402671A2 (hu) 2005-04-28
WO2003072555A1 (de) 2003-09-04
CA2477031A1 (en) 2003-09-04
DE10208987A1 (de) 2003-09-11
JP2005519085A (ja) 2005-06-30
HUP0402671A3 (en) 2006-07-28
PL370423A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
EP1445258B1 (en) Activator for peroxisome proliferator-activated receptor delta
EP1725231A1 (en) Triazole, oxadiazole and thiadiazole derivatives as ppar modulators for the treatment of diabetes
US20100041721A1 (en) Selective androgen receptor modulators
WO2012026495A1 (ja) 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
US5594004A (en) Compound with platelet aggregation inhibitor activity
US6596742B1 (en) Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use in medicaments
EP2463279B1 (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
KR20040095240A (ko) 치환된 3-페닐-5-알콕시-1,3,4-옥사디아졸-2-온, 이의제조방법 및 약물에서의 이의 용도
KR20040101250A (ko) 췌장 리파제를 억제하는 약제를 제조하기 위한 치환된3-페닐-5-알콕시-1,3,4-옥스디아졸-2-온의 용도
US6900233B2 (en) Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
EP2468737B1 (en) Sulfone derivative
CN112204018B (zh) 一类丙烯酸类化合物及其制备方法、药物组合物和用途
EP1940815B1 (en) Salts of modulators of ppar and methods of treating metabolic disorders
US6339083B1 (en) Multiheterocyclic pharmAceuticals
HK1171011B (en) Sulfone derivative
HK1171010B (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
HK1107763A1 (en) Crth2 receptor ligands for medicinal uses
HK1107763B (en) Crth2 receptor ligands for medicinal uses

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040827

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid